Kaposi's sarcoma is a malignant tumour that commonly arises in immunocompromised individuals as the result of infection with Kaposi's-sarcoma-associated herpesvirus (KSHV), but little is known about what cells it arises from or how it progresses. Two articles in the July issue of Nature Genetics use gene-expression profiling to show that KSHV activates expression of lymphatic-specific genes, indicating new therapeutic avenues.
Kaposi's sarcoma mainly affects cells of the skin, and most tumour cells express endothelial-cell markers. Chris Boshoff and colleagues used gene-expression analysis to compare the profiles of Kaposi'ssarcoma biopsy samples to normal skin cells. They found that Kaposi'ssarcoma cells expressed a large percentage of lymphatic endothelial cell (LEC)-associated genes, such as vascular endothelial growth factor receptor 3 (VEGFR3), angiopoietin 2 (ANG2), podoplanin and CD206. They also expressed some genes that were specific to blood-vessel endothelial cells (BECs). Similarly, Detmar's group used geneexpression analysis to show that KSHV infection of human dermal microvascular endothelial cells resulted in upregulation of 70% of lymphatic-lineage-specific genes.
So, which cells become infected with KSHV? Boshoff 's group assayed viral infection and replication in several vascular cell types and found that LECs, followed by BECs, were the most susceptible to KSHV infection. They concluded that when the virus infects vascular endothelial cells, they become transcriptionally reprogrammed to express primarily lymphatic-vesselspecific genes, although some BECspecific genes are also induced. The resulting change in cellular phenotype might help the virus to replicate more efficiently, exploiting LEC differentiation pathways to promote its own life cycle. When this differentiation goes awry, Kaposi's sarcoma develops. This is reminiscent of human papillomavirus (HPV)-induced cervical cancer, where HPV exploits squamous-cell differentiation to complete its life cycle.
What are the cellular targets of the virus that can cause this switch in gene expression? The homeobox gene PROX1 is a master gene that controls lymphatic-vessel development and differentiation, and is specifically expressed by LECs. Detmar's group showed that KSHV infection resulted in an eightfold upregulation of PROX1. Boshoff also observed that PROX1 was moderately upregulated in Kaposi's-sarcoma cells, relative to normal skin.
So, KSHV seems to reprogramme endothelial-cell transcriptomes towards a primarily lymphatic phenotype. This is likely to be partially mediated by viral upregulation of PROX1, although both authors predict that other cellular or viral genes are also likely to be involved. As lymphangiogenic molecules such as ANG2 and VEGFD are upregulated in the plasma of patients with Kaposi's sarcoma, they might be good candidates for treatment with newly developed anti-lymphangiogenic therapies.
Therefore, PAK1 phosphorylation of DLC1 seems to be required for cell survival and tumour formation. Furthermore, DLC1 levels were increased in 90% of the human breast tumour samples that the authors analysed.
How Cytoskeletal proteins regulate cell adhesion and motility, and some have even been shown to mediate cell survival. In the June issue of Cancer Cell, Rakesh Kumar and colleagues report the surprising finding that two cytoskeletal proteins, p21-activated kinase 1 (PAK1) and the dynein light chain 1 (DLC1), interact to promote the survival and tumorigenic potential of breast cancer cells.
Kumar and colleagues began their studies by looking for new substrates of PAKs. PAKs phosphorylate RHO GTPases to control cytoskeletal organization, and also phosphorylate and inactivate the pro-apoptotic protein BAD to promote survival. In a yeast two-hybrid screen of a mammarygland cDNA library, they found that PAK1 interacts directly with, and also phosphorylates, DLC1 -a component of the dynein motor complex. DLC1 not only regulates the microtubule-dependent motor function of dynein, but has also been shown to bind and inhibit activity of the pro-apoptotic protein BimL.
So what happens when these two pro-survival signalling proteins get together? Kumar and colleagues expressed normal and mutant forms of the proteins in a breast cancer cell line, and showed that the interaction between PAK1 and DLC1 is required for cell-cycle progression and survival. Cells that overexpressed either PAK1 or DLC1 were able to undergo anchoragei n d e p e n d e n t growth, indicating a malignant p h e n o t y p e , and also led to oestrogen-independent tumour growth when transplanted into nude mice, unlike control cells. A DLC mutant that lacked the PAK1 phosphorylation site did not show tumorigenic potential in mice.
Two of a kind
NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Biswas, D.K. et al. Proc. Natl Acad. Sci. USA 101, 10137-10142 (2004) Oestrogen-receptor-negative breast tumours represent a significant therapeutic hurdle because of a lack of effective molecular targets. Biswas et al. show that tumours that are oestrogen-receptornegative but ERBB2-positive express increased levels of activated NF-κB. Suppression of NF-κB induced apoptosis in proliferating breast carcinoma cells, indicating that it might be a therapeutic target in these tumours.
SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Hamamoto, R. et al. Nature Cell Biol. 4 July 2004 (doi:10.1038 Methylation of DNA and its associated histones is important for the activation and repression of transcription. Hamamoto et al. show that SMYD3 is overexpressed in most colorectal and liver tumours. A specific domain in SMYD3 was found to methylate histone H3 and -as part of a complex of proteins that includes RNA polymerase II -SMYD3 regulates the transcription of several important cell-cycle control genes. The deregulated expression of SMYD3 in these tumours might be a key factor in their development.
Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Burgess, A. et al. Oncogene 5 July 2004 (doi:10.1038 Burgess and colleagues show that histone deacetylase inhibitors (HDIs) kill non-proliferating tumour cells, but not normal cells. The mechanism of cytotoxicity in non-proliferating cells involves the activation of the cyclin-dependent kinase inhibitor WAF1 -the same pathway that is activated by HDIs in proliferating cells -but non-proliferating cells take longer to activate the apoptosis machinery. Therefore, HDIs might be useful in the treatment of slowly proliferating tumours.
Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Menendez, J. A. et al. Proc. Natl Acad. Sci. USA 2 July 2004 (doi:10.1073 Levels of fatty-acid synthase (FAS) -an essential enzyme in the conversion of dietary carbohydrates to fatty acids -increase during breast cancer development, and hyperactivity of FAS is associated with aggressive disease. Javier Menendez et al. show that increased FAS activity in breast and ovarian cancer cell lines has an active role in malignant transformation by regulating key oncogenes, such as ERBB2.
G E N E E X P R E S S I O N T H E R A P E U T I C S T U M O R I G E N E S I S B R E A S T C A N C E R
The retinoblastoma tumour suppressor (RB) is a key regulator of the cell cycle; its loss prevents cell-cycle arrest and induces apoptosis in many tissues. These findings prompted speculation that the tumour 'cell of origin' for retinoblastoma would be one that has acquired an anti-apoptotic mutation. However, two separate groups have reached the similar and surprising conclusion that, in mice, the cell of origin for this tumour is naturally resistant to the effects of Rb loss.
The Jacks and co-workers also studied retinas with a conditional Rb deletion. In one approach, Rb function was disrupted within almost all cells of the retina, nervous system and other tissues (Rb mosaics) and these mice were crossed with p107 -/-or p130 -/-mice. The Rb mosaic p130 -/-mice developed retinoblastoma with histology very similar to human tumours, indicating that, like p107, p130 might compensate for Rb loss in mice. In another approach, Jacks and colleagues used the same αCre/Rb lox/lox mice as the Bremner lab to accurately determine retinal cell fate in the absence of Rb only. They observed similar results to the Bremner lab, concluding that apoptotic and S-phase cells corresponded primarily with terminally differentiating cells. Given that loss of Rb predisposes terminally differentiating retinal cells to apoptosis, which cells survive to go on to form tumours? Both groups found that four terminally differentiated cell types -ganglion, rod, cone and bipolar cells -were lost, whereas some horizontal, Muller glia and amacrine cells survived. The survival of amacrine cells might explain why Rb loss leads to amacrine-rich retinoblastomas in Rb -/-p107 -/-or Rb -/-p130 -/-mice. But why do amacrine cells survive when other cell types do not? Both research groups conclude that amacrine cells are more resistant to Rb loss and can survive the many rounds of replication that result before they terminally differentiate. Therefore, the retinoblastoma cell of origin arises from a pool of intrinsically apoptosis-resistant differentiating precursors with extended, but finite, division capacity. These cells presumably undergo further mutations to evade terminal differentiation. Discovering this particular property of the cell of origin should help identify both further mutations that are involved in the development of human retinoblastoma and novel tumour therapy targets. Hamartomas are benign lesions that develop in a range of dominantly inherited tumour syndromes, including tuberous sclerosis complex (TSC) and Peutz-Jeghers syndrome (PJS). Two groups now have evidence for a molecular link between TSC and PJS.
Nicola McCarthy
Although developing in different tissues, the hamartomas seen in patients with either TSC or PJS have a similar histology. One of the known phosphorylation targets of the PJS tumour-suppressor kinase LKB1 is the energy-sensing AMP kinase (AMPK), which is activated by high AMP (low ATP) levels. TSC2 -a tumour suppressor involved in TSC and a regulator of target of rapamycin (TOR) kinase -is a direct target of AMPK, prompting Corradetti et al. and Shaw et al. to look closely at the molecular pathways disrupted through the loss of Lkb1.
Both groups initially verified that LKB1 can negatively regulate phosphorylation of the TOR kinase substrates S6 kinase and 4EBP1. Phosphorylation of both of these proteins was increased in cells with non-functional LKB1. Both groups then examined the regulation of this pathway by manipulating the activity of AMPK. Shaw and co-workers used an AMP mimetic to stimulate AMPK and showed that TSC2 was phosphorylated only in the presence of functional LKB1. Corradetti and colleagues used an AMPK inhibitor to show that LKB1 was unable to alter the phosphorylation status of S6 kinase in the absence of functional AMPK.
What is the physiological relevance of these findings? TOR is a component of the energy-sensing pathway and Tsc2 -/-cells undergo apoptosis when deprived of glucose, a response that is blocked by the TOR inhibitor rapamycin. Both groups demonstrate the same sensitivity and response to rapamycin in Lkb1 -/-cells in the absence of glucose. Corradetti and colleagues showed that, like Tsc2 -/-cells, Lkb1 -/-cells secrete increased levels of vascular endothelial growth factor, which is attenuated in the presence of rapamycin. Shaw and colleagues have also found that Lkb1 +/-mice develop intestinal hamartomas that mimic those arising in patients with PJS and these also have increased levels of TOR activity.
Therefore, the similarities between PJS and TSC are because of LKB1 and TSC2 belonging to the same kinase signalling pathway. Their affect on TOR also indicates that rapamycin and its analogues could be used to treat hamartomas in these patients. However, despite these similarities, intriguing questions remain. Why, for example, do patients with PJS develop hamartomas in the intestine, whereas patients with TSC have widespread tissue involvement? One explanation might be that loss of TSC2 function affects more than energy signalling pathways; Tsc2 -/-cells also fail to respond to growthfactor-mediated pathways that remain intact in Lkb1 -/-cells. The authors conclude that a likely mechanism of B-cell depletion by anti-CD20 mAbs is FcγR-mediated phagocytosis of mAb-coated B cells by macrophages. This knowledge should help to understand the response and resistance to rituximab therapy and the development of effective methods to enhance the benefits of therapies for non-Hodgkin's lymphoma.
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The vaccine, called PANVAC-VF, was developed by Therion Biologics Corporation. It includes recombinant vaccinia and fowlpox viruses that coexpress CEA and MUC1, which are expressed by over 90% of pancreatic tumour cells. The vaccine also incorporates the costimulatory molecules B7.1, ICAM1 and LFA to enhance and sustain the antitumour immune response.
In Phase I studies of 22 patients with advanced pancreatic cancer, 20 of whom had metastatic disease, vaccination with PANVAC-VF resulted in a median overall survival of 7.9 months and at least 5.3 months. This is in comparison to an anticipated median overall survival of approximately 3 months, based on historical controls. The most common adverse event was a reaction at the injection site, but no serious side effects were observed. A multicentre, randomized, controlled Phase III trial is underway, enrolling 250 patients with advanced pancreatic cancer who have not responded to treatment with gemcitabine. The primary end point will be overall survival, compared with palliative chemotherapy or best supportive care. The study will also determine safety, quality of life, change in serum tumour antigen levels, response rate and disease stabilization.
Immunotherapies targeted at CEA and MUC1 have also been tested in patients with other tumours that are known to overexpress the CEA and MUC1 antigens, including breast, lung and colorectal cancers. Therion and the National Cancer Institute are now planning up to 18 additional studies with PANVAC-VF in patients with these cancers.
ORIGINAL RESEARCH PAPER Schuetz, T. et al. Two phase I studies of prime-boost vaccinations with vaccinia-fowlpox vaccines expressing CEA, MUC-1, and TRICOM costimulatory molecules (B7.1/ICAM-1/ LFA-3) in patients with advanced pancreatic cancer. Am. Soc. Clin. Oncol. abstract 2564 (2004 Cardiotoxicity reduced A novel anthracycline, pixantrone, has been given fast-track status by the Food and Drug Administration for relapsed, aggressive non-Hodgkin's lymphoma. Anthracyclines, such as doxorubicin, are part of standard treatment for non-Hodgkin's lymphoma together with cyclophosphamide, vincristine and prednisone (CHOP). However, anthracyclines are associated with cumulative heart damage that limits their use in patients previously treated with anthracyclines and prohibits their use in many others.
Pixantrone (made by Cell Therapeutics Inc.) is easier to administer than doxorubicin and has not shown the same risk of cardiac damage. The drug design was based on the anthracycline mitoxantrone -the OH groups thought to cause free-radical production and cardiotoxicity were removed and replaced with nitrogen. The molecule is still planar, so the substitution does not effect intercalation into DNA, where the drug causes its damage.
Cell Therapeutics tested single-agent pixantrone in 30 patients with aggressive non-Hodgkin's lymphoma who had already received 300 mg/m 2 doxorubicin, which would normally make them ineligible for further anthracycline treatment. Five patients had a complete response and four had a partial response; responses lasted an average of 11 months. Pixantrone is now being studied in combination, replacing doxorubicin in CHOP, and preliminary results of 22 patients have shown 13 with complete responses and four with partial responses. Pixantrone was well tolerated, with neutropaenia as the dose-limiting toxicity.
Other trials, including a Phase II trial of pixantrone with rituximab in relapsed indolent non-Hodgkin's lymphoma, are ongoing.
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